Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics has disclosed Other Non-Current Liabilities across 8 years of filings, most recently posting $37.8 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $37.8 million, up 1340.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.8 million (up 1340.78% YoY), and the FY2025 annual result was $43.5 million, up 22.94% from the prior year.
• Other Non-Current Liabilities came in at $37.8 million for Q1 2026 at Insight Molecular Diagnostics, down from $43.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $57.2 million in Q2 2022 to a low of $2.0 million in Q2 2024.
• The 5-year median for Other Non-Current Liabilities is $37.8 million (2026), against an average of $28.3 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 95.6% in 2023 and surged 2022.9% in 2025, its largest moves.
• Insight Molecular Diagnostics' Other Non-Current Liabilities stood at $42.6 million in 2022, then slipped by 5.71% to $40.2 million in 2023, then decreased by 12.02% to $35.3 million in 2024, then grew by 22.94% to $43.5 million in 2025, then decreased by 13.0% to $37.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $37.8 million (Q1 2026), $43.5 million (Q4 2025), and $43.9 million (Q3 2025), per Business Quant data.